Security
MetaVia Inc. Common Stock · MTVA
MTVANASDAQCommon stockCurrentCIK 1638287Updated Nov 6, 2026
Name history
NeuroBo Pharmaceuticals, Inc. · through Nov 18, 2024Gemphire Therapeutics Inc. · through Dec 31, 2019
MTVA price & chart
Loading TradingView…
NASDAQ:MTVA on TradingView ↗About the company
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of various cardiometabolic conditions, with potential in both Metabolic and Alcohol-Associated Liver Disease (MetALD) and Alcohol-Associated Liver Disease (ALD), and is advancing vanoglipel (DA-1241) in combination with resmetirom for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist, engineered with a 3:1 GLP1R:GCGR potency ratio. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure. In a Phase 1 Part 3B interim analysis at Day 109, DA-1726 demonstrated placebo-adjusted reductions of 13.5% in body weight, 68% in liver fat and 0.24 percentage points in HbA1c, along with reductions in visceral and subcutaneous adipose tissue and relatively preserved lean mass. A Phase 2, 48-week, non-biopsy study of DA-1726 in MetALD and ALD, is targeted to begin in…
In the news
MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering News provided by MetaVia, Inc. Jan 15, 2026, 09:32 ET Share this article Share to X Share this article Share to X CAMBRIDGE, Mass. , Jan. 15, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA ) (MetaVia or the Company), a clin ↗
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
10-Q filing
Show 5 more recent filings
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Other Events
Items 8.01, 9.01
424B5 filing
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 14,765,000Source | 22,146,000Source | 13,271,000Source | 18,459,000Source | 28,751,000Source | 14,388,000Source | 12,127,000Source | 17,018,000Source | 11,123,000Source | 16,260,000Source | 22,781,000Source | 33,534,000Source |
| Property, Plant and Equipment, NetUSD | 22,000Source | 39,000Source | 8,000Source | 27,000Source | 44,000Source | 12,000Source | 30,000Source | 47,000Source | 17,000Source | 34,000Source | 46,000Source | 2,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 14,277,000Source | 21,669,000Source | 12,634,000Source | 17,589,000Source | 27,934,000Source | 13,731,000Source | 11,190,000Source | 15,988,000Source | 10,278,000Source | 16,017,000Source | 22,435,000Source | 33,364,000Source |
| Assets, CurrentUSD | 14,646,000Source | 21,935,000Source | 13,067,000Source | 18,315,000Source | 28,517,000Source | 14,162,000Source | 11,961,000Source | 16,764,000Source | 10,875,000Source | 16,072,000Source | 22,512,000Source | 33,532,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 369,000Source | 266,000Source | 433,000Source | 726,000Source | 583,000Source | 431,000Source | 771,000Source | 776,000Source | 597,000Source | 55,000Source | 77,000Source | — |
| Operating Lease, Right-of-Use AssetUSD | 76,000Source | 151,000Source | 175,000Source | 96,000Source | 169,000Source | 193,000Source | 115,000Source | 186,000Source | 210,000Source | 133,000Source | 202,000Source | — |
| Other Assets, NoncurrentUSD | 21,000Source | 21,000Source | 21,000Source | 21,000Source | 21,000Source | 21,000Source | 21,000Source | 21,000Source | 21,000Source | 21,000Source | 21,000Source | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 8,434,000Source | 9,193,000Source | 6,449,000Source | 8,835,000Source | 9,809,000Source | 5,315,000Source | 7,747,000Source | 6,942,000Source | 5,790,000Source | 8,329,000Source | 6,096,000Source | 11,784,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 24,000Source | 9,000Source | 7,000Source | 24,000Source | 8,000Source | 5,000Source | 9,000Source | 5,000Source | 2,000Source | 9,000Source | 5,000Source | 25,000Source |
| Additional Paid in CapitalUSD | 153,207,000Source | 143,628,000Source | 164,784,000Source | 153,123,000Source | 143,966,000Source | 161,721,000Source | 143,899,000Source | 125,050,000Source | 154,161,000Source | 143,779,000Source | 124,945,000Source | 117,520,000Source |
| Retained Earnings (Accumulated Deficit)USD | -146,900,000Source | -130,684,000Source | -157,969,000Source | -143,523,000Source | -125,032,000Source | -152,653,000Source | -139,528,000Source | -114,979,000Source | -148,830,000Source | -135,857,000Source | -108,265,000Source | -95,795,000Source |
| Stockholders' Equity Attributable to ParentUSD | 6,331,000Source | 12,953,000Source | 6,822,000Source | 9,624,000Source | 18,942,000Source | 9,073,000Source | 4,380,000Source | 10,076,000Source | 5,333,000Source | 7,931,000Source | 16,685,000Source | 21,750,000Source |
| Liabilities and EquityUSD | 14,765,000Source | 22,146,000Source | 13,271,000Source | 18,459,000Source | 28,751,000Source | 14,388,000Source | 12,127,000Source | 17,018,000Source | 11,123,000Source | 16,260,000Source | 22,781,000Source | 33,534,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 8,434,000Source | 9,114,000Source | 6,346,000Source | 8,820,000Source | 9,711,000Source | 5,192,000Source | 7,710,000Source | 6,825,000Source | 5,648,000Source | 8,271,000Source | 5,960,000Source | 11,784,000Source |
| Operating Lease, Liability, CurrentUSD | 79,000Source | 75,000Source | 74,000Source | 83,000Source | 72,000Source | 71,000Source | 81,000Source | 70,000Source | 68,000Source | 78,000Source | 67,000Source | — |
| Accounts Payable, CurrentUSD | 2,599,000Source | 1,017,000Source | 921,000Source | 2,875,000Source | 2,632,000Source | 1,007,000Source | 3,054,000Source | 2,079,000Source | 1,060,000Source | 3,879,000Source | 821,000Source | 708,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 79,000Source | 103,000Source | 15,000Source | 98,000Source | 123,000Source | 37,000Source | 117,000Source | 142,000Source | 58,000Source | 136,000Source | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | — | — | — | — | — | — | 3,948,000Source | — | — | 4,414,000Source | 280,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 100,000Source | 132,000Source | 411,000Source | 538,000Source | 222,000Source | 854,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -301,000Source | -825,000Source | -2,819,000Source | 3,058,000Source | 113,000Source | -202,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -2,413,000Source | -8,401,000Source | -3,248,000Source | 26,331,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -4,258,000Source | -4,815,000Source | -15,701,000Source | -24,710,000Source | -10,799,000Source | -11,712,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | -2,000Source | -8,000Source | -50,000Source | 8,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 2,000Source | 8,000Source | 50,000Source | — |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | 12,000Source | 12,000Source | 48,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 7,711,000Source | -12,000Source | 9,964,000Source | 18,300,000Source | -80,000Source | 28,681,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 14,277,000Source | 21,669,000Source | 12,634,000Source | 17,589,000Source | 13,731,000Source | 11,190,000Source | 10,278,000Source | 16,017,000Source | 22,435,000Source | 33,364,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 97,000Source | 139,000Source | 130,000Source | 111,000Source | 132,000Source | 100,000Source | 411,000Source | 538,000Source | 222,000Source | — |
| DepreciationUSD | — | — | 5,000Source | 5,000Source | 4,000Source | 5,000Source | 5,000Source | 4,000Source | 19,000Source | 20,000Source | 6,000Source | 20,000Source |
| Financing Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 2,191,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | — | — | — | — | — | — | — | — | — | -4,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | -75,000Source |
| General and Administrative ExpenseUSD | — | — | 1,561,000Source | 1,742,000Source | 1,907,000Source | 1,981,000Source | 1,924,000Source | 1,559,000Source | 6,906,000Source | 7,256,000Source | 6,728,000Source | 8,640,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,377,000Source | -5,652,000Source | -5,316,000Source | -3,995,000Source | -3,823,000Source | -3,671,000Source | -12,973,000Source | -27,592,000Source | -12,470,000Source | -13,967,000Source |
| Operating ExpensesUSD | — | — | 3,475,000Source | 6,259,000Source | 5,385,000Source | 4,301,000Source | 4,025,000Source | 3,886,000Source | 13,708,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | — | — | 98,000Source | 607,000Source | 69,000Source | 306,000Source | 202,000Source | 215,000Source | 735,000Source | 1,217,000Source | 3,416,000Source | 5,661,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | — | 1,651,000Source | 80,000Source | 3,569,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -3,475,000Source | -6,259,000Source | -5,385,000Source | -4,301,000Source | -4,025,000Source | -3,886,000Source | -13,708,000Source | -28,809,000Source | -15,886,000Source | -19,628,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 98,000Source | 607,000Source | 69,000Source | 306,000Source | 202,000Source | 215,000Source | 735,000Source | 1,217,000Source | 3,416,000Source | 5,661,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -3,377,000Source | -5,652,000Source | -5,316,000Source | -3,995,000Source | -3,823,000Source | -3,671,000Source | -12,973,000Source | -27,592,000Source | -12,470,000Source | -13,967,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,377,000Source | -5,652,000Source | -5,316,000Source | -3,995,000Source | -3,823,000Source | -3,671,000Source | -12,973,000Source | -27,592,000Source | -12,470,000Source | -13,967,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.14Source | -0.55Source | -0.9Source | -2.87Source | -0.79Source | -3.93Source | -7.35Source | -3.56Source | -2.46Source | -5.43Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.14Source | -0.55Source | -0.9Source | -2.87Source | -0.79Source | -3.93Source | -7.35Source | -3.56Source | -2.46Source | -5.43Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 24,415,876Source | 10,214,087Source | 5,931,875Source | 1,389,753Source | 4,859,567Source | 933,109Source | 1,766,026Source | 7,757,128Source | 5,071,101Source | 2,573,624Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 24,415,876Source | 10,214,087Source | 5,931,875Source | 1,389,753Source | 4,859,567Source | 933,109Source | 1,766,026Source | 7,757,128Source | 5,071,101Source | 2,573,624Source |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | — | 6,259,000Source | — | — | — | 3,886,000Source | — | 28,809,000Source | 15,886,000Source | 19,628,000Source |
| Financing Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 2,191,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | — | — | — | — | — | — | — | — | — | -4,000Source |
| General and Administrative ExpenseUSD | — | — | 1,561,000Source | 1,742,000Source | 1,907,000Source | 1,981,000Source | 1,924,000Source | 1,559,000Source | 6,906,000Source | 7,256,000Source | 6,728,000Source | 8,640,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -12,973,000Source | -27,592,000Source | -12,468,000Source | -14,559,000Source |
| Interest Income (Expense), NetUSD | — | — | 151,000Source | 310,000Source | 73,000Source | 146,000Source | 85,000Source | 128,000Source | 510,000Source | 920,000Source | 461,000Source | — |
| Operating ExpensesUSD | — | — | 3,475,000Source | 6,259,000Source | 5,385,000Source | 4,301,000Source | 4,025,000Source | 3,886,000Source | 13,708,000Source | — | — | — |
| Research and Development ExpenseUSD | — | — | 1,914,000Source | 4,517,000Source | 3,478,000Source | 2,320,000Source | 2,101,000Source | 2,327,000Source | 6,802,000Source | — | — | — |
Offerings
Registration 333-280865
Registration 333-292581
- Gross proceeds
- 8099987.7
- Net proceeds
- 7370988.8
- Deal price
- 3.1
- Shares
- 2612899
- Offering price
- $3.10
- Ticker
- MTVA
Underwriters: Ladenburg Thalmann & Co. Inc.
Registration 333-292743
Filing attachments
mtva-ex99d1.htm · 8-K · 2026-11-05
Exhibit 99.1 MetaVia Announces Statistically Significant 68% Reduction in Liver Fat from DA-1726 Phase 1 Part 3B Interim Data DA-1726 Also Demonstrated Statistically Significant 13.5% Placebo-Adjusted Weight Loss and Reduced Mean HbA1c from 5.79% to 5.33% in Participants Without Diabetes No New Gastrointestinal Adverse Events Were Reported After Week 9 Through Day 109, with No Gastrointestinal Adverse Events Leading to Study Discontinuation Full Part 3A and Part 3B Data Expected in the First…
Read attachment ↗mtva-ex99d2.htm · 8-K · 2026-11-05
Exhibit 99.2 1 MetaVia Inc. Transforming Cardiometabolic Diseases November 2026 Nasdaq: MTVA MetaVia Inc. — DA -1726 & vanoglipel programs, November 2026 ────────────────────────────────────────────── 2 Disclaimers This presentation (this “Presentation”) includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current fac…
Read attachment ↗mtva-ex99d1.htm · 8-K · 2026-10-28
Exhibit 99.1 MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026 CAMBRIDGE, Mass., October 28, 2026 - MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from the Phase 1 clinical trial of DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors, has been accepted…
Read attachment ↗mtva-ex99d1.htm · 8-K · 2026-10-13
Exhibit 99.1 MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer Brings Extensive Experience Leading Liver and Metabolic Disease Drug Development Programs, Including MASH, and Successfully Advancing Therapies Through Phase 2 and Into Phase 3 Development Deep Expertise in Dual GLP-1/Glucagon Receptor Agonist Development, Including Pemvidutide CAMBRIDGE, Mass., October 13, 2026 - MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology compa…
Read attachment ↗mtva-20260909xex99d1.htm · 8-K · 2026-09-09
EX-99.1 2 mtva-20260909xex99d1.htm EX-99.1 Exhibit 99.1 MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction Tissue Distribution Study Shows Highest Exposure in Adipose Tissue and Prolonged Retention Consistent with Once-Weekly Dosing Findings Provide Mechanistic Support for the Differentiated Profile of DA-1726 CAMBRIDGE, Mass., September 9, 2026 - MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on …
Read attachment ↗mtva-20260806xex99d1.htm · 8-K · 2026-08-06
EX-99.1 2 mtva-20260806xex99d1.htm EX-99.1 Exhibit 99.1 MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update All Active Patients Successfully Reached Highest Planned Dose Levels of 48 mg and 64 mg in Ongoing Phase 1 Part 3 Study of DA-1726 16-Week Topline Data Expected in the Fourth Quarter of 2026 CAMBRIDGE, Mass., August 6, 2026 - MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today an…
Read attachment ↗